None of the 29 investors followed here reported a position in RAPP in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RAPP trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | Ceesay Abraham NChief Executive Officer | Sale at price 30.66 - 32.03 per share. | 4.5K | $143.27K |
| Sep 29, 2026 | Gault CherylChief Operating Officer | Sale at price 33.04 - 33.76 per share. | 10K | $331.86K |
| Sep 22, 2026 | Ceesay Abraham NChief Executive Officer | Sale at price 34.13 - 39.86 per share. | 2.2K | $86.27K |
| Sep 7, 2026 | Ceesay Abraham NChief Executive Officer | Sale at price 45.56 - 46.01 per share. | 8.2K | $374.50K |
| Aug 24, 2026 | Ceesay Abraham NChief Executive Officer | Sale at price 49.57 per share. | 18.9K | $937.96K |
| Aug 24, 2026 | Yeleswaram KrishnaswamyOfficer | Sale at price 50.00 - 51.06 per share. | 50.2K | $2.53M |
| Aug 18, 2026 | Yeleswaram KrishnaswamyOfficer | Sale at price 49.90 per share. | 404 | $20.16K |
| Aug 10, 2026 | Ceesay Abraham NChief Executive Officer | Sale at price 45.97 - 48.62 per share. | 51.5K | $2.43M |
| Jul 26, 2026 | Ceesay Abraham NChief Executive Officer | Sale at price 42.11 - 42.74 per share. | 2.2K | $93.06K |
| Jul 13, 2026 | Ceesay Abraham NChief Executive Officer | Sale at price 39.72 - 40.57 per share. | 8.2K | $328.44K |
| Jun 29, 2026 | Gault CherylChief Operating Officer | Sale at price 40.09 - 43.15 per share. | 10K | $415.80K |
| Jun 28, 2026 | Ceesay Abraham NChief Executive Officer | Sale at price 39.77 - 40.34 per share. | 8.2K | $327.40K |
| May 25, 2026 | Third Rock Ventures V, L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 40.05 per share. | 18.6K | $743.75K |
| May 10, 2026 | Third Rock Ventures V, L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 40.24 per share. | 133.6K | $5.38M |
| May 7, 2026 | Third Rock Ventures V, L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 40.12 - 40.31 per share. | 276.5K | $11.09M |
| Apr 16, 2026 | Third Rock Ventures V, L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 40.32 per share. | 426K | $17.18M |
| Apr 16, 2026 | Yeleswaram KrishnaswamyOfficer | Sale at price 39.99 per share. | 20.2K | $808.84K |
| Apr 13, 2026 | Yeleswaram KrishnaswamyOfficer | Sale at price 34.97 - 35.08 per share. | 19.9K | $695.82K |
| Apr 7, 2026 | Yeleswaram KrishnaswamyOfficer | Sale at price 34.90 per share. | 360 | $12.56K |
| Mar 29, 2026 | Gault CherylChief Operating Officer | Sale at price 28.04 - 28.55 per share. | 10K | $281.86K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.3 | 9.1 | 7.8 | 5.9 | 19.2 | 5.5 | -1.7 | 18.8 | -31.0 | -10.3 | −0.6% | ||
| 2025 | -7.5 | -38.9 | 0.0 | 14.2 | -27.8 | 37.5 | 26.3 | 22.8 | 68.5 | -2.6 | 2.7 | 2.1 | +71.0% |
| 2024 | -2.3 | -4.3 | -5.8 | 19.8 | -6.9 | -22.3 | −23.7% |
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Buy / hold / sell counts